Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 4
2012 12
2013 5
2014 11
2015 6
2016 3
2017 4
2018 6
2019 4
2020 9
2021 16
2022 19
2023 12
2024 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Results by year

Filters applied: . Clear all
Page 1
Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies.
Privé BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW, van Lith SAM, Mehra N, Nagarajah J, Heskamp S, Westdorp H. Privé BM, et al. Among authors: nagarajah j. Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):1906-1918. doi: 10.1007/s00259-023-06144-0. Epub 2023 Feb 23. Eur J Nucl Med Mol Imaging. 2023. PMID: 36813980 Free PMC article. Review.
PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.
Uijen MJM, Derks YHW, Merkx RIJ, Schilham MGM, Roosen J, Privé BM, van Lith SAM, van Herpen CML, Gotthardt M, Heskamp S, van Gemert WAM, Nagarajah J. Uijen MJM, et al. Among authors: nagarajah j. Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4350-4368. doi: 10.1007/s00259-021-05433-w. Epub 2021 Jun 12. Eur J Nucl Med Mol Imaging. 2021. PMID: 34120192 Free PMC article. Review.
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.
Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. Fizazi K, et al. Among authors: nagarajah j. Lancet Oncol. 2023 Jun;24(6):597-610. doi: 10.1016/S1470-2045(23)00158-4. Lancet Oncol. 2023. PMID: 37269841 Free PMC article. Clinical Trial.
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.
Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Študentová H, Nagarajah J, Mellado B, Montesa-Pino Á, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K; PSMAfore Investigators. Morris MJ, et al. Among authors: nagarajah j. Lancet. 2024 Sep 28;404(10459):1227-1239. doi: 10.1016/S0140-6736(24)01653-2. Epub 2024 Sep 15. Lancet. 2024. PMID: 39293462 Clinical Trial.
Iodine Symporter Targeting with 124I/131I Theranostics.
Nagarajah J, Janssen M, Hetkamp P, Jentzen W. Nagarajah J, et al. J Nucl Med. 2017 Sep;58(Suppl 2):34S-38S. doi: 10.2967/jnumed.116.186866. J Nucl Med. 2017. PMID: 28864610 Free article. Review.
PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study.
van Lith SAM, Pruis IJ, Tolboom N, Snijders TJ, Henssen D, Ter Laan M, Te Dorsthorst M, Leenders WPJ, Gotthardt M, Nagarajah J, Robe PA, De Witt Hamer P, Hendrikse H, Oprea-Lager DE, Yaqub M, Boellaard R, Wesseling P, Balvers RK, Verburg FA, Harteveld AA, Smits M, van den Bent M, van Zanten SEMV, van de Giessen E. van Lith SAM, et al. Among authors: nagarajah j. J Nucl Med. 2023 Oct;64(10):1526-1531. doi: 10.2967/jnumed.123.265738. Epub 2023 Aug 31. J Nucl Med. 2023. PMID: 37652540 Free article.
Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study.
Weber M, Kersting D, Riemann B, Brandenburg T, Führer-Sakel D, Grünwald F, Kreissl MC, Dralle H, Weber F, Schmid KW, Herrmann K, Jentzen W, Grafe H, Rischpler C, Theurer S, Bockisch A, Nagarajah J, Fendler WP. Weber M, et al. Among authors: nagarajah j. Clin Cancer Res. 2022 Oct 3;28(19):4194-4202. doi: 10.1158/1078-0432.CCR-22-0437. Clin Cancer Res. 2022. PMID: 35594174 Free PMC article.
Urinary excretion kinetics of [177Lu]Lu-PSMA-617.
de Bakker M, Dominicus N, Meeuwis A, Janssen M, Konijnenberg MW, Nagarajah J, Peters SMB. de Bakker M, et al. Among authors: nagarajah j. Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3572-3575. doi: 10.1007/s00259-023-06328-8. Epub 2023 Jul 8. Eur J Nucl Med Mol Imaging. 2023. PMID: 37421427 Free PMC article.
111 results